The Ledger / Frederik Paulsen
Frederik Paulsen
◼ Origin
Son of Frederick Paulsen Sr., who founded Ferring Pharmaceuticals in 1950 in Malmö, Sweden, building it into a specialty biopharmaceutical company focused on reproductive medicine, maternal health, gastroenterology, and urology; Frederik Paulsen Jr. inherited the company and serves as chairman of the privately-held group, which is headquartered in Saint-Prex, Switzerland and employs 7,000+ people across more than 60 countries. Ferring is best known for its reproductive medicine portfolio (including Menopur and Bravelle for ovarian stimulation), the urology drug desmopressin (DDAVP), and its investigational gene therapy program; the company is privately held with majority ownership retained in the Paulsen family.
◼ Self-Made Verdict — INHERITED
Son of Frederick Paulsen Sr. who founded Ferring Pharmaceuticals in 1950; Frederik Jr. inherited the controlling ownership and chairmanship of a fully-built specialty pharmaceutical company with established products, global distribution, and $1B+ in revenues. His wealth reflects the inherited value of his father's original entrepreneurship, not original business creation.
◼ Documented marks
01
Chairman of Ferring Pharmaceuticals, a privately held specialty biopharmaceutical company headquartered in Saint-Prex, Switzerland, founded by his father Frederick Paulsen Sr. in 1950 and now one of the world's leading companies in reproductive medicine, maternal health, urology, and gastroenterology; Ferring employs 7,000+ people in more than 60 countries and generates revenues estimated at $2B+. Key products include gonadotropins (Menopur, Bravelle) for ovarian stimulation in IVF, desmopressin (DDAVP/Minirin) for enuresis and diabetes insipidus, and the synthetic prostaglandin carbetocin for prevention of postpartum hemorrhage. Ferring's private ownership under the Paulsen family allows long-horizon R&D investments without public market quarterly earnings pressure.
02
Ferring has been a pioneer in the application of gene therapy to reproductive medicine: the company developed relugolix (commercialized as Orgovyx, later licensed to Myovant Sciences/Pfizer) for endometriosis and uterine fibroids, and has invested substantially in in vivo gene therapy approaches through its Ferring Gene Therapy unit. These investments — made over 10+ year development horizons — are cited as a distinctive example of how private, family-controlled pharmaceutical companies can pursue long-duration scientific programs that public companies with quarterly earnings pressure would likely avoid.
03
Ferring's global pricing practices for reproductive medicine products have been a subject of international healthcare policy debate: the company's fertility drugs (used in IVF cycles that cost US patients $15,000-$30,000 per cycle) carry significant price variation across markets — substantially higher in the US than in European markets — contributing to IVF access disparities that have been documented by fertility medicine advocacy organizations. No major formal regulatory enforcement action against Ferring or the Paulsen family has been documented in public record, though the broader practice of multi-market price discrimination for fertility drugs has attracted academic and policy scrutiny.
No inheritance, or primary accounts documented for this billionaire yet.
◼ List of charges
No documented charges yet.
These are moral charges, not legal ones. The actual legal system has not — and will not — bring them.
More ledger entries